Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
2.110
+0.060 (2.93%)
Nov 21, 2024, 12:09 PM EST - Market open
Allogene Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2017 |
| Revenue | 0.04 | 0.1 | 0.16 | 114.09 | - | - | Upgrade
|
| Revenue Growth (YoY) | 26.47% | -39.10% | -99.86% | - | - | - | Upgrade
|
| Cost of Revenue | 201.99 | 242.91 | 256.39 | 220.18 | 192.99 | 144.54 | Upgrade
|
| Gross Profit | -201.95 | -242.82 | -256.23 | -106.09 | -192.99 | -144.54 | Upgrade
|
| Selling, General & Admin | 66.91 | 71.67 | 79.31 | 74.11 | 65.26 | 57.47 | Upgrade
|
| Operating Expenses | 66.91 | 71.67 | 79.31 | 74.11 | 65.26 | 57.47 | Upgrade
|
| Operating Income | -268.86 | -314.49 | -335.54 | -180.19 | -258.24 | -202.01 | Upgrade
|
| Interest Expense | -0.1 | - | - | - | - | - | Upgrade
|
| Interest & Investment Income | 23.39 | 18.31 | 4.57 | 1.71 | 8.86 | 17.35 | Upgrade
|
| Earnings From Equity Investments | -4.49 | -10.67 | -12.88 | -4.09 | -67.31 | -0.18 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.41 | -0.16 | 3.44 | 0.52 | 0.31 | -0.09 | Upgrade
|
| EBT Excluding Unusual Items | -250.47 | -307.02 | -340.41 | -182.05 | -316.38 | -184.93 | Upgrade
|
| Gain (Loss) on Sale of Investments | -4 | -7 | - | - | - | - | Upgrade
|
| Asset Writedown | -28.96 | -13.25 | - | - | - | - | Upgrade
|
| Pretax Income | -283.43 | -327.27 | -340.41 | -182.05 | -316.38 | -184.93 | Upgrade
|
| Income Tax Expense | - | - | - | - | - | -0.33 | Upgrade
|
| Net Income | -283.43 | -327.27 | -340.41 | -182.05 | -316.38 | -184.59 | Upgrade
|
| Net Income to Common | -283.43 | -327.27 | -340.41 | -182.05 | -316.38 | -184.59 | Upgrade
|
| Shares Outstanding (Basic) | 184 | 157 | 143 | 136 | 120 | 101 | Upgrade
|
| Shares Outstanding (Diluted) | 184 | 157 | 143 | 136 | 120 | 101 | Upgrade
|
| Shares Change (YoY) | 22.14% | 9.63% | 5.39% | 12.84% | 19.11% | 249.11% | Upgrade
|
| EPS (Basic) | -1.54 | -2.09 | -2.38 | -1.34 | -2.63 | -1.83 | Upgrade
|
| EPS (Diluted) | -1.54 | -2.09 | -2.38 | -1.34 | -2.63 | -1.83 | Upgrade
|
| Free Cash Flow | -217.93 | -239.25 | -225.71 | -206.26 | -181.05 | -188.14 | Upgrade
|
| Free Cash Flow Per Share | -1.18 | -1.52 | -1.58 | -1.52 | -1.50 | -1.86 | Upgrade
|
| Gross Margin | - | - | - | -92.99% | - | - | Upgrade
|
| Operating Margin | -625246.51% | -331044.21% | -215087.18% | -157.94% | - | - | Upgrade
|
| Profit Margin | -659137.21% | -344489.47% | -218214.10% | -159.57% | - | - | Upgrade
|
| Free Cash Flow Margin | -506806.98% | -251841.05% | -144685.90% | -180.79% | - | - | Upgrade
|
| EBITDA | -254.97 | -300.29 | -321.24 | -169.74 | -250.81 | -197.58 | Upgrade
|
| EBITDA Margin | - | - | - | -148.78% | - | - | Upgrade
|
| D&A For EBITDA | 13.88 | 14.2 | 14.3 | 10.45 | 7.44 | 4.42 | Upgrade
|
| EBIT | -268.86 | -314.49 | -335.54 | -180.19 | -258.24 | -202.01 | Upgrade
|
| EBIT Margin | - | - | - | -157.94% | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.